Roche reports Phase 3 data for satralizumab in SatraGO-1, SatraGO-2

Roche (RHHBY) presented at ASPORS meeting primary results of the Phase 3 SatraGO-1 and SatraGO-2 trials — Efficacy and Safety of Satralizumab in Thyroid Eye Disease. The SatraGO-1 study in active TED failed to meet its primary endpoint — proptosis response at week 24 — with placebo-adjusted rates of 18%-30%. The SatraGO-2 study met its primary endpoint of proptosis response — 53% vs. 23%. The company said that “Satralizumab showed clinically meaningful improvements across key efficacy endpoints, including proptosis, diplopia, and CAS inactive TED. The safety profile of satralizumab in TED was highly favorable, with no reports of AEs commonly associated with other treatments for TED.”